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The absence of readily available animal and cell culture models for hepatitis C virus (HCV) replication has bottlenecked
research on protective immunity to HCV infection. Antibodies reactive with HCV virions in vitro are assumed to be candidates
for neutralizing or inhibitory antibodies against HCV. To find potentially neutralizing or inhibitory antibody candidates, anti-C,
anti-E1, anti-E2, and anti-HVR1 antisera acquired from mice immunized with corresponding recombinant proteins or synthetic
peptides were used to capture HCV viral particles in vitro based on antibody–virus interaction assays. Both anti-E2 and
anti-HVR1 antibodies effectively captured HCV in vitro. Furthermore, it was found that anti-E2 and anti-HVR1 antibodies could
immunoprecipitate an isolate of HCV unrelated to the original antigenic HCV isolate. ELISA confirmed that anti-HVR1
antibodies cross-reactively bind to these unrelated HVR1 peptides. These findings suggest that anti-E2 and anti-HVR1
antibodies induced in mice have the ability to bind with HCV particles in an isolate cross-reactive manner and highlight the
possible application of combining several sequences of HVR1 to generate broadly reactive anti-HVR1 antibodies. © 1998
Academic Press
INTRODUCTION
After viral infection, the host immune system produces
antibodies specific to the infecting pathogen. Neutraliz-
ing antibody, which binds to and inactivates the virion,
plays an important role in the prevention of and possibly
recovery from viral infection. Viral antigens that stimulate
neutralizing antibodies have previously been used suc-
cessfully as vaccines.
Hepatitis C virus (HCV) is the major etiological agent
of posttransfusional non-A non-B hepatitis. Most HCV-
infected individuals will develop chronic hepatitis with an
attendant risk of cirrhosis, liver failure, and hepatocellu-
lar carcinoma. HCV probably persists because of the
emergence of mutant viruses that escape the host im-
mune system (Weiner et al., 1992). It is vital to identify
critical epitopes that elicit a neutralizing antibody re-
sponse to understand the pathogenesis of persistent
infection and to develop effective vaccines. The roles of
the putative HCV glycoproteins E1 and E2 in virus neu-
tralization remain unknown, although chimpanzees im-
munized with recombinant E1 and E2 proteins were
protected from HCV challenge (Choo et al., 1994). The
hypervariable region 1 (HVR1) of the E2 protein is a
candidate neutralizing epitope; however, emergence of
an escape mutant during flareups of HCV infection or
after interferon treatment makes it difficult to exploit this
finding for therapeutic and prophylactic purposes (Kato
et al., 1993; Weiner et al., 1992).
The absence of a cell culture system for propagation of
HCV in vitro and the lack of a readily available animal model
for HCV replication in vivo have impeded research on pro-
tective immunity to HCV infection. The recent development
of methods of assessing of neutralizing antibodies against
HCV confirm that after infection, HCV-induced antibodies
bind to virions and prevent initiation of viral replication
(Shimizu et al., 1994). Therefore, the assessment of anti-
body that can bind to HCV particles may be an initial step
in finding a candidate for neutralizing antibody. We previ-
ously found that an immune response against HCV struc-
tural proteins was highly induced in actively immunized
mice and that the murine immune system might be a target
for studying potentially protective activity against HCV in-
fection (Ahmed et al., 1996). In the present study, to find
potentially neutralizing or inhibitory antibody candidates in
actively immunized sera, murine antisera against C, E1, E2,
and HVR1 of HCV viral polypeptides were tested for the
ability to capture HCV.
RESULTS
Virus capture by immunized mouse sera
Recombinant E1 and E2 glycoproteins derived from
HCV-N2 and a mixture of synthetic peptides of HVR1
quasispecies from HCV-#6 were used to immunize mice
and were found to be immunogenic based on reactivity
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between mouse antisera and antigenic peptides on an
ELISA plate (Table 1 and Fig. 1). The immune responses
against HVR1 peptides were higher in the C57BL/6, C3H/
He, and BDF1 strains of mice and somewhat lower in
BALB/c mice (Table 1). Figure 1 shows the epitope map-
ping of anti-E1, anti-E2, and anti-HVR1 antibodies in im-
munized mice. In the E1 protein, four peptides located in
the N-terminal 50-amino-acid (aa) region (aa 192–241)
showed positive responses in immunized mice (Fig. 1A).
Of the 29 synthetic peptides in the E2 region, five pep-
tides located in the middle portion, peptides 9–11 (aa
464–503) and peptides 14–15 (aa 514–543), were found to
be positive in all immunized mice, whereas other pep-
tides showed various reactivities in individual mice (Fig.
1B). However, the immune sera against E2 protein in all
three mice showed no reactivity to the corresponding
HVR1 region (Fig. 1B) because the recombinant E2 pro-
tein used was constructed from a region of aa 390–683
and lacked six aa residues at the N terminus of HVR1.
The immune sera from all mice that were immunized with
a mixture of HVR1 peptides, #6–1, #6–2, and #6–3, were
reactive to the corresponding initial 20 aa (aa 384–403)
and were marginally or not reactive to aa 394–413 or aa
404–423 of the corresponding sequences (Fig. 1C). This
indicates that the immunodominant region of the HVR1
sequence is located in the first 20 aa, aa 384–403. Thus
the E1, E2, and HVR1 epitopes showed high immune
responses in immunized mice.
These immune sera were used to capture the virus by
immunoprecipitation assay using anti-mouse immuno-
globulin as a second antibody. As shown in Fig. 2, high-
titer anti-E2 and anti-HVR1 antisera were able to capture
all detectable HCV-#6. No detectable HCV RNA re-
mained in the supernatants of anti-E2 (E2-a, E2-b) and
anti-HVR1 (B6-b, C3H-a, BD-a, BD-b), and HCV RNA was
found only in the precipitates. These findings suggest
that almost all of the HCV particles were captured by
anti-E2 or anti-HVR1 antibodies and the immune com-
plexes of HCV were subsequently precipitated by the
second antibody. Even the comparatively lower titers of
anti-HVR1 antibodies, such as from BALB/c mice, could
partially capture HCV in one of two mice (BALB-b of
anti-HVR1). Anti-C and anti-E1 antisera, however, were
unable to capture HCV, and HCV RNA was detected only
in the supernatants; there was no detectable HCV RNA in
the precipitates after the addition of the second antibod-
ies. These findings demonstrate that immunization with
HCV structural proteins E2 and HVR1 can elicit an im-
mune response in mice that has the ability to form
antigen–antibody complexes with HCV.
We then determined whether the virus-capturing ability
of immune sera is isolate specific. A panel of 16 chronic
hepatitis C patient sera was tested for the presence of
HCV immune complexes. Diluted sera were mixed with
anti-human immunoglobulin, incubated for 1 h at 4°C,
and then centrifuged to separate pellets and superna-
tants, and RNA was detected by RT-PCR. HCV from five
chronic hepatitis C patients was found to be free of
immune complex (#3, #5, #7, #11, and #16) (data not
shown), and these samples were used as the HCV
source in subsequent cross-immunoprecipitation exper-
iments. As shown in Fig. 3, HCV RNA from one of these
five serum samples, #7, could be detected in the precip-
itates after interaction of HCV with anti-HVR1-#6 antisera
(B6-b, BD-b, and C3H-a) or anti-E2 antiserum (E2-a);
there was no detectable HCV RNA in the supernatants.
TABLE 1
Titers of Anti-E1, Anti-E2, and Anti-HVR1 Antibodies in Immunized Mouse Sera
Mouse n Anti-E1 Anti-E2
Anti-HVR1a
#6-1 #6-2 #6-3
C57BL/6 3 7000–13,000
(10,000)
C57BL/6 3 15,000–38,000
(30,000)
C57BL/6 3 6000–14,000 1800–6500 7500–19,000
(9500) (4500) (13,000)
C3H/He 3 5200–22,000 7500–22,000 10,000–22,000
(12,000) (13,000) (15,000)
BALB/c 3 1800–15,000 550–1500 1200–6000
(8600) (1000) (4100)
BDF1 3 950–22,000 240–3000 1750–12,000
(10,000) (1800) (6400)
Note. To determine antibody titers, serial dilutions of immune sera were incubated in antigen-coated wells. The titers were determined as the
dilution number indicating the half-maximum absorbance value at 450 nm in ELISA. Normal mouse sera were used as negative controls and showed
no reactivity with any coated antigens. Values in parentheses are mean titers of antibodies.
a Anti-HVR1 antiserum was produced by immunizing mice with a mixture of three HVR1 peptides, #6-1, #6-2, and #6-3; the antibody response was
determined separately against the three peptides.
159CROSS-REACTIVE ANTIBODY WITH HCV CAPTURE ACTIVITY
This indicates that both anti-HVR1-#6 and anti-E2 of
HCV-N2 antibodies can cross-capture HCV virions #7.
None of the other four HCV isolates, #3, #5, #11, or #16,
could be captured by any antisera because HCV RNA
was detected only in the supernatants, not in the precip-
itates.
Sequence analysis of HVR1
We investigated whether the determinants of this
cross-immunoprecipitation could be observed at the nu-
cleotide sequence level in HCV HVR1. We sequenced
immunoprecipitable HCV isolate #7 and nonimmunopre-
cipitable HCV isolates #3 and #16. The deduced aa
sequences of these three isolates are shown and com-
pared with those of #6 quasispecies in Fig. 4A. The HVR1
sequences of #7, #3, and #16 were determined by those
of 15, 12, and 7 subclones, which were identical within
each isolate, respectively. The homology of the deduced
aa sequence in HVR1 (31–33 aa) between #6 and #7 was
57–63%, and the homology between #6 and nonimmu-
noprecipitable isolates #3 and #16 was 47–53% and
53–60%, respectively. As shown in Fig. 4B, phylogenetic
analysis of these nucleotide sequences in the presence
of unrelated HVR1 sequences indicated that there was
no close association between #7 and #6. These findings
suggest that aa sequence homology alone does not
explain the cross-immunoprecipitation of HCV isolates.
Cross-reactivity of HVR1 sequences
To confirm the cross-reactivity of virus capturing, we
examined the cross-reactivity of anti-HVR1-#6 with pep-
tide HVR1-#7 by ELISA. Anti-HVR1-#6 antiserum showed
similar antibody titers against both peptides HVR1-#6
and HVR1-#7 but no reactivity against peptide HVR1-#3
FIG. 1. Immunoreactive peptide mapping of immunized mouse sera. Immune sera were obtained from different mice immunized with E1 and E2
proteins of HCV-N2 and a mixture of three HVR1 peptides of HCV-#6, respectively, and diluted 100-fold for ELISA using a series of 10-mer overlapping
20-aa peptides as coated antigens. (A and B) Antigenic regions of E1 protein (A) and E2 protein (B) were identified by 13 peptides covering aa 192–331
and 29 peptides covering aa 384–682, respectively. The first two peptides of E2 (B) correspond to the hypervariable region 1 (HVR1) of HCV-N2. The
three different bars represent different C57BL/6 mice. (C) Antigenic regions of HVR1 sequences were identified by three 20-aa peptides from each
of three quasispecies: #6–1, #6–2, and #6–3. HVR1 peptides 1, 2, and 3 spanned aa residues 384–403, 394–413, and 404–423, respectively. Four strains
of mice were immunized: f, C57BL/6; M, C3H/He; z, BDF1, and o, BALB/c.
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or HVR1-#16 (Fig. 5). Hence, antibodies against HVR1-#6
were able to recognize HVR1 sequences not only from
the original antigenic HCV isolate but from other HCV
isolates, facilitating capture of other viral particles.
DISCUSSION
In the present study, we demonstrated that anti-E2 and
anti-HVR1 antibodies induced in the sera of immunized
mice immunoprecipitated HCV in vitro in an isolate
cross-reactive manner based on an antibody–virus inter-
action assay. This suggests that the antibody binding
sites involved in immunoprecipitation are probably
present on the surface of HCV particles. Antibodies that
can bind with a virion do not always have neutralizing
ability, but the evidence that anti-E2 or anti-HVR1 anti-
bodies bind with HCV fulfills the prerequisite for these
antibodies to inactivate HCV.
To elucidate protective immunity to HCV infection,
some studies have focused on the humoral immune
response to structural proteins of HCV. Chimpanzees
immunized with recombinant E1 and E2 glycoproteins
were protected against homologous HCV challenge
(Choo et al., 1994), but it is not known whether such
protection requires combined E1 and E2 immunization or
which region or regions are critical for protection. On the
other hand, neutralizing antibodies were found to be
induced after natural HCV infection. Plasma containing
isolate-specific anti-virion antibodies from an HCV-
infected patient neutralized homologous HCV infection in
vitro (Shimizu et al., 1994) and in vivo (Farci et al., 1994).
Recently, these investigators provided direct evidence
that anti-HVR1 antibodies have neutralizing ability. Anti-
bodies against HVR1 from rabbits immunized with syn-
thetic peptides neutralized HCV in vitro (Shimizu et al.,
1996) and in vivo (Farci et al., 1996). However, the isolate-
specific function of these anti-HVR1 antibodies is a major
impediment to the development of effective vaccines
from HVR1. In this study, we provided additional evidence
that anti-HVR1 antibodies produced in immunized mice
could bind with HCV virion (Fig. 2) and also found that
these capturing antibodies were not isolate specific but
cross-reactive (Fig. 3).
The mechanism of cross-recognition of anti-E2 and
anti-HVR1 antibodies in virus capture is not yet known.
ELISA data have shown that anti-E2 has no reactivity to
the HVR1 sequence (Fig. 1), and other region or regions
FIG. 2. PCR-based virus capture assays with antisera from immunized mice. After preincubation of HCV-#6 and antisera, bound and free of viral
particles were separated by centrifugation into precipitate (ppt) and supernatant (sup) following the addition of anti-mouse IgG. Each sup and ppt were
tested for the presence of HCV RNA by RT-PCR; cDNA from each sup and ppt was diluted 100- to 104-fold (shown on the top of each lane) and then
subjected to PCR. Antisera from two mice each (a and b) were examined, and anti-HVR1 antiserum was produced by immunizing four strains of mice
(B6, C3H, BALB, and BD) with a mixture of HVR1-#6 peptides. None indicates capture assay was performed in the absence of antiserum and
subsequently in the presence of second antibody; NMS, normal mouse serum was added instead of antiserum. At least two independent experiments
were performed, and representative results are shown.
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may be responsible for the recognition of anti-E2 anti-
bodies. For example, two regions, aa 464–503 and aa
514–543, were immunoreactive in peptide ELISA and
may be involved in cross-recognition of virus capture.
Conformational epitope or epitopes also may be candi-
date cross-recognition sites. In regard to anti-HVR1,
ELISA data have indicated that anti-HVR1 antibodies
induced by immunization with a mixture of #6–1, #6–2,
and #6–3 contained binding activity to HVR1-#7 in addi-
tion to these three peptides. Moreover, anti-HVR1 anti-
bodies against one of the three HVR1-#6 peptides, #6–1,
were found to be cross-reactive with the whole se-
quence of HVR1 peptides #7 (31 aa) but not reactive with
any of the 20 aa peptides of #7 (data not shown). Thus
conformational flexibility may be involved in this cross-
reactivity. On the other hand, anti-HVR1-#7 antibodies
produced in the immunized mice were also found to be
reactive to HVR1-#6 peptides #6–1, #6–2, and #6–3 (data
not shown). This mutual immunological cross-reactivity
between HVR1-#6 and HVR1-#7 corroborated the phe-
nomenon of cross-reactivity found in the capture assay.
We initially confirmed that anti-C and anti-E1 antibod-
ies could not effectively capture HCV, based on the
antibody–virus interaction assay. The failure of anti-C
antibodies to capture HCV may be because the C protein
constitutes the nucleocapsid of HCV. However, antibod-
ies against E1 protein, which is one of two HCV envelope
proteins, showed binding activity with HCV in an immu-
noelectron microscopic study (Kaito et al., 1994). The
possible reasons for this discrepancy might be (1) E1
protein derived from different expression systems results
in different immunogenicity or (2) different lengths of the
E1 gene were expressed.
Our present work goes further in demonstrating the
possibility that the reactive spectrum of anti-HVR1 anti-
bodies can be broadened. The cross-reactivity of these
antibodies must be confirmed in further experiments
because the cross-reactivity of anti-HVR1 antibodies is
crucial in designing HCV vaccines if the HVR1 turns out
to be a neutralizing epitope. Encouragingly, it was re-
ported that anti-HVR1 antibodies in some HCV-infected
patients were cross-reactive when synthetic HVR1 pep-
tides were used (da Silva Cardoso et al., 1995; Scarselli
et al., 1995). We also found that anti-HVR1-#6 antibodies
were cross-reactive to several HVR1 sequences in addi-
tion to HVR1-#7 (data not shown). Furthermore, the an-
tibody response against HVR1-#6 in a chimpanzee was
also high and the antibodies were able to cross-capture
HCV #7 (unpublished data). Therefore, the preliminary
FIG. 3. PCR-based virus cross-capture assays with antisera from
immunized mice. Antisera against a mixture of HVR1-#6 (B6-b, BD-b,
and C3H-a) and anti-E2 antiserum (E2-a) were assessed for the ability
to capture five samples of HCV, #3, #5, #7, #11, and #16. HCV-#7 was
captured by antiserum, and HCV RNA was found in the precipitate but
not in the supernatant. NMS indicates normal mouse serum. Two
independent experiments were performed, and the same results were
obtained.
FIG. 4. Sequence analysis of HVR1. (A) Deduced aa sequences of
HVR1. #6–1, #6–2, and #6–3 are quasispecies of HCV-#6, and a mixture
of these three 31-aa HVR1 peptides was used as an immunogen to
produce anti-HVR1 antisera. The HCV-N2 sequences were used to
produce anti-E1 and anti-E2 antisera. The #3 and #16 HCVs had an
insert mutation of two aa and one aa, respectively. Dashes indicate
residues identical to those of #6–1. Asterisks indicate gaps relative to
insert mutant sequences. (B) Phylogenetic tree of HVR1 nucleotide
sequences. The sequences of the initial 111-bp region of E2 were
phylogenetically analyzed by adding five reference sequences, includ-
ing N2, whose synthetic peptides proved not to be reactive to antibod-
ies against HVR1-#6 by ELISA (data not shown). Bootstrap analysis
was performed 1000 times, and calculated values are shown at each
branch.
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data suggest that cross-reaction of anti-HVR1 antibodies
is not a rare event. There is hope that a combination of
several HVR1 cross-reactive sequences may generate
anti-HVR1 antibodies that will react with broad spectrum
of HCV isolates.
MATERIALS AND METHODS
Immunization of mice
C57BL/6 mice were immunized with NCC (aa 1–120), a
core peptide produced in Escherichia coli (Esumi et al.,
1996) and with VLKG3738 (aa 192–330) and VLKG3031 (aa
390–683), which are truncated E1 and E2 glycoproteins,
respectively, that are produced in insect cells (Nishihara et
al., 1993) as described previously (Ahmed et al., 1996).
These C, E1, and E2 sequences were derived from pN4.1
(accession no. D13406 in DDBJ/EMBL/GenBank) based on
HCV-N2 of genotype 1b (Hayashi et al., 1993). The se-
quences of immunogen HVR1 peptides were derived from
aa 384–414 of HCV-#6 with quasispecies of HCV (Esumi et
al., 1994) and were as follows: HTRVTGGVQGHVTSTLTSL-
FRPGASQKIQLV (HVR1-#6–1), DTHVTGAVQGHGAFGLTS-
LFTSGASQKIQLV (HVR1-#6–2), and NTHVTGAVQGHGAF-
GLTSLFQPGASQKIQLV (HVR1-#6–3). The C-terminal cys-
teine-containing HVR1 peptides were synthesized on an
automated multipeptide synthesizer PSSM-8 (Shimadzu,
Kyoto, Japan) and conjugated with Imject maleimide-acti-
vated keyhole limpet hemocyanin (KLH) (Pierce, Rockford,
IL) according to the manufacturer’s instructions. The conju-
gates containing 30 mg of each of three HVR1 peptides
(#6–1, #6–2, and #6–3) were mixed and then injected into
three mice of each strain (C57BL/6, C3H/He, BALB/c, and
BDF1) three times at 10-day intervals. The final booster of
HVR1-KLH conjugates was performed 7 weeks after the
third injection. One week after the final booster injection,
mice were killed to allow collection of whole blood for
antibody analysis.
Peptide synthesis and indirect ELISA
A series of peptides (20 aa each), each overlapping
the adjacent peptide by 10 aa, were synthesized. A total
of 51 peptides (13 from E1, 29 from E2, and nine from
HVR1) were synthesized to span the recombinant E1, E2,
and HVR1 peptides used in this work. Peptides including
a 31-aa HVR1 peptide were synthesized on a PSSM-8
(Shimadzu) and purified by HPLC using a SynProPep
column (type RPC18, 20 mm 3 150 mm; Shimadzu). The
sequences of the peptides were confirmed by aa se-
quencing using a protein sequencer PSQ10 (Shimadzu).
Indirect ELISA was performed as described previously
(Ahmed et al., 1996).
Patient sera
Serum samples were obtained from 17 chronic hepa-
titis C patients with high titers of serum HCV RNA (105 to
106 copies/50 ml of serum). Immune complexes of HCV in
the serum samples were examined by immunoprecipita-
tion of HCV with anti-human IgG (Organon Teknika,
Durham, NC) as described previously (Hijikata et al.,
1993). Six of the 17 samples were free of immune com-
plex and were used for virus capture.
Virus capture
The virus capture activity of antisera was assessed by
the modified method for immune complex analysis of
HCV in patient sera (Hijikata et al., 1993). Fifty microliters
of 10223 diluted HCV patient sera was centrifuged at
16,000 rpm for 15 min, and the supernatant was mixed
with 1 ml of immunized mouse sera. The mixtures were
incubated for 1 h at 4°C, and 50 ml of 2 mg/ml of
anti-mouse IgG goat F(ab9)2 (Organon Teknika) was
added. After a second incubation for 1 h at 4°C, the
mixtures were centrifuged at 2800 rpm for 15 min and
separated into supernatants and pellets. Both superna-
tant and pellet were mixed with RNA isolation reagent
TRIzol (Life Technologies, Gaithersburg, MD) to extract
and test HCV RNA by RT-PCR. To examine capture ac-
tivity semiquantitatively, cDNA from supernatant and pre-
cipitate was serially diluted 10-fold and subjected to
PCR. If HCV RNA was detected only in the pellet and not
in the supernatant, it meant that HCV had been captured.
If HCV RNA was contained in both pellet and superna-
tant, it suggested that HCV had been partially captured.
The presence of HCV RNA in the supernatant alone
indicated no capture.
RT-PCR
RT and a two-step PCR assay with nested primers
were performed to detect the 59-untranslated region of
HCV RNA. In the RT reaction, 100 pmol of random primer
was used to prime cDNA synthesis from HCV RNA by
200 U of Moloney murine leukemia virus reverse tran-
FIG. 5. Binding activity of anti-HVR1-#6 antiserum to various HVR1
peptides. Serial dilutions of anti-HVR1-#6 antiserum (BD-b) were as-
sessed for binding to various HVR1 peptides (#6–1, #6–2, #6–3, #3, #7,
and #16) on an ELISA plate. The aa sequences of coated HVR1
peptides are shown in Fig. 4A.
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scriptase (Life Technologies) in 20 ml of the reaction
mixture for 90 min at 37°C. For PCR, an external primer
pair, 59-CACTCCCCTGTGAGGAACTA-39 (forward) and 59-
GGTGCACGGTCTACGAGACC-39 (reverse), were used,
followed by an internal primer pair, 59-TTCACGCAGAA-
AGCGTCTAG-39 (forward) and 59-CCCTATCAGGCAGTA-
CCACA-39 (reverse) at 15 pmol in 50 ml of the reaction
mixture. To amplify the HVR1 of the HCV genome, an
external primer pair, 59-GCGGGCCTTGCCTACTATTC-39
(forward) and 59-GGGCATCCGGACGAGTTGAA-39 (re-
verse), and an internal primer pair, 59-CATGGCGGGGA-
ACTGGGCTAAGGT-39 (forward) and 59-CAGGGCAGTC-
CTGTTGATGTGCCA-39 (reverse), were used for PCR.
PCR was performed using Taq DNA polymerase (Life
Technologies) with 35 cycles of 30 s at 94°C, 45 s at
55°C, and 1 min at 72°C, followed by extension for 10
min at 72°C.
Subcloning and sequencing
To determine the HVR1 nucleotide sequence of HCV in
selected serum samples, serum RNA was extracted and
subjected to RT-PCR of the HVR1. The PCR product was
purified and ligated into T-tailed pGEM4Z vector by a T-A
overhang cloning method (Marchuk et al., 1991), and the
plasmid was used to transform E. coli JM109 competent
cells (TOYOBO, Osaka, Japan). Seven to 18 subcloned
DNAs of each sample were sequenced by a cycle se-
quencing method with primers end-labeled using T4
polynucleotide kinase (TOYOBO) and [g-32P]ATP (6000
Ci/mmol; NEN Life Science Products, Boston, MA). The
nucleotide sequences were translated by the DNASIS
program version 3.6 (Hitachi Software Engineering Co.,
Ltd., Yokohama, Japan). The nucleotide sequences of
HVR1, including reference HVR1 sequences (unpub-
lished data), were aligned, and the bootstrap analysis
was performed by the Clustal W program version 1.5
(Thompson et al., 1994).
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